Literature DB >> 1696638

Linear B-cell epitopes of the major core protein of human immunodeficiency virus types 1 and 2.

B Janvier1, P Archinard, B Mandrand, A Goudeau, F Barin.   

Abstract

Nine murine monoclonal antibodies directed to the major core protein p24 of human immunodeficiency virus type 1 (HIV-1) were obtained and then tested by using an epitope mapping system (Pepscan) covering the whole p24HIV1 protein to characterize antigenic domains. Four different linear epitopes were identified. Monoclonal antibodies recognizing three of these epitopes also reacted to p26HIV2 in Western blotting (immunoblotting). A monoclonal antibody specific for the fourth epitope, located at position 179 to 188 of the gag polyprotein p55HIV1 (human T-cell lymphotropic virus type 3B strain), did not react with HIV type 2 (HIV-2) core proteins. The corresponding sequence is constant in all known HIV-2 and simian immunodeficiency virus (SIV) isolates, including a very divergent SIV strain from African green monkeys (SIVagm/tyo). This observation may be relevant to the phylogeny of primate lentiviruses. Two of the conserved epitopes might be immunogenic during natural infection and could therefore be used for diagnosis and prognosis purposes. These two epitopes are AAEWDRVHP and EIYKRWII, starting at positions 209 and 260 of the polyprotein p55HIV1, respectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696638      PMCID: PMC247891     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Three-dimensional structure of poliovirus at 2.9 A resolution.

Authors:  J M Hogle; M Chow; D J Filman
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

3.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

4.  Antibody responses in early human immunodeficiency virus type 1 infection in hemophiliacs.

Authors:  M J Chou; T H Lee; A Hatzakis; T Mandalaki; M F McLane; M Essex
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

5.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

6.  Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.

Authors:  F Barin; M F McLane; J S Allan; T H Lee; J E Groopman; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

7.  Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus.

Authors:  J M Lange; R A Coutinho; W J Krone; L F Verdonck; S A Danner; J van der Noordaa; J Goudsmit
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-25

8.  Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa.

Authors:  F Barin; S M'Boup; F Denis; P Kanki; J S Allan; T H Lee; M Essex
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

9.  Antibody response in primary human immunodeficiency virus infection.

Authors:  H Gaines; M von Sydow; A Sönnerborg; J Albert; J Czajkowski; P O Pehrson; F Chiodi; L Moberg; E M Fenyö; B Asjö
Journal:  Lancet       Date:  1987-05-30       Impact factor: 79.321

10.  Variation in human T lymphotropic virus III (HTLV-III) antibodies in homosexual men: decline before onset of illness related to acquired immune deficiency syndrome (AIDS).

Authors:  R J Biggar; M Melbye; P Ebbesen; S Alexander; J O Nielsen; P Sarin; V Faber
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-12
View more
  6 in total

1.  Characterization of immune responses to capsid protein p24 of human immunodeficiency virus type 1 and implications for detection.

Authors:  Shixing Tang; Jiangqin Zhao; Aifeng Wang; Ragupathy Viswanath; Harri Harma; Richard F Little; Robert Yarchoan; Susan L Stramer; Phillipe N Nyambi; Sherwin Lee; Owen Wood; Eric Y Wong; Xue Wang; Indira K Hewlett
Journal:  Clin Vaccine Immunol       Date:  2010-06-09

2.  Epitope analysis of capsid and matrix proteins of North American ovine lentivirus field isolates.

Authors:  K A Marcom; L D Pearson; C S Chung; J M Poulson; J C DeMartini
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

3.  Immune response to a major epitope of p24 during infection with human immunodeficiency virus type 1 and implications for diagnosis and prognosis.

Authors:  B Janvier; A Baillou; P Archinard; M Mounier; B Mandrand; A Goudeau; F Barin
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

4.  Comparative humoral responses to human immunodeficiency virus type 1-p24gag linear B-cell epitopes among individuals showing atypical western immunoblotting reactions and implications for diagnosis.

Authors:  J C Lallement; J P Vendrell; P Corbeau; J Ducos; M Segondy; A Escande; V Robert-Hebmann; F Jean; J Reynes; A Serre
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

5.  Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics.

Authors:  H J de Haard; B Kazemier; M J Koolen; L J Nijholt; R H Meloen; B van Gemen; H R Hoogenboom; J W Arends
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

6.  Characterization of Humoral Immune Responses against Capsid Protein p24 and Transmembrane Glycoprotein gp41 of Human Immunodeficiency Virus Type 1 in China.

Authors:  Xiufen Li; Yue Wu; Xuqi Ren; Shuyun Deng; Guifang Hu; Shouyi Yu; Shixing Tang
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.